Pacira BioSciences, Inc. $PCRX Shares Sold by Bridge City Capital LLC

Bridge City Capital LLC lessened its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 8.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 285,493 shares of the company’s stock after selling 25,951 shares during the quarter. Pacira BioSciences accounts for 2.2% of Bridge City Capital LLC’s portfolio, making the stock its 5th largest position. Bridge City Capital LLC owned 0.66% of Pacira BioSciences worth $7,389,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of PCRX. Hantz Financial Services Inc. grew its position in shares of Pacira BioSciences by 175.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock worth $29,000 after acquiring an additional 721 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Pacira BioSciences by 5,900.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock valued at $39,000 after acquiring an additional 1,475 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Pacira BioSciences in the 4th quarter valued at approximately $48,000. Eurizon Capital SGR S.p.A. bought a new stake in shares of Pacira BioSciences in the 4th quarter valued at approximately $51,000. Finally, Global Retirement Partners LLC increased its holdings in shares of Pacira BioSciences by 479.4% in the 4th quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock valued at $52,000 after acquiring an additional 1,678 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Insider Activity at Pacira BioSciences

In related news, SVP Lauren Riker sold 6,115 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the transaction, the senior vice president owned 62,284 shares in the company, valued at $1,463,674. The trade was a 8.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Shawn Cross sold 12,941 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $25.16, for a total value of $325,595.56. Following the transaction, the chief financial officer owned 105,341 shares of the company’s stock, valued at $2,650,379.56. This represents a 10.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 34,376 shares of company stock worth $846,312 in the last 90 days. 6.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PCRX. Barclays lowered their price target on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a report on Thursday, March 26th. Weiss Ratings upgraded Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, May 20th. Wall Street Zen downgraded Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Needham & Company LLC boosted their price target on Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a report on Friday, May 1st. Finally, Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $29.40.

Pacira BioSciences Trading Down 1.6%

NASDAQ:PCRX opened at $22.99 on Friday. Pacira BioSciences, Inc. has a 12-month low of $18.80 and a 12-month high of $27.64. The firm has a market capitalization of $904.61 million, a P/E ratio of 191.60 and a beta of 0.29. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.73 and a quick ratio of 3.35. The business has a 50 day simple moving average of $23.58 and a 200 day simple moving average of $23.27.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings data on Thursday, April 30th. The company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Pacira BioSciences had a net margin of 0.70% and a return on equity of 10.24%. The company had revenue of $177.38 million for the quarter, compared to analyst estimates of $171.80 million. During the same quarter in the prior year, the firm earned $0.65 EPS. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Equities research analysts predict that Pacira BioSciences, Inc. will post 1.91 EPS for the current year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.